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KEY ENZYMES IN CANCER: MECHANISM OF ACTION 
AND INHIBITION WITH ANTICANCER AGENTS 
Debasish Bandyopadhyay ", Gabriel Lopezt, 
Stephanie Cantu t, Samantha Balboat, Annabel Garcia t, 
Christina Silvat and Diandra Valdest 
Department of Chemistry, The University of Texas Rio Grande Valley, 
Edinburg, Texas, US 
A heartfelt tribute to the memory of Professor Asima Chatterjee, the legendary 
scientist-teacher-humanitarian, on the occasion of her birth centenary (1917-2017). 
ABSTRACT 
Several enzymes play significant role in different stages of cancer including 
proliferation, invasion, metastasis and angiogenesis. Mechanism of actions of a few key 
enzymes along with their inhibitors have been discussed with particular attentation to 
riboneucleotide reductase, thymidylate synthease, topoisomerase II, interleukins, cell 
survival proteins and aminopeptidase N. 
Keywords: cancer, enzyme, riboneucleotide reductase, thymidylate synthease, topoisomerase 
II, cell survival proteins, aminopeptidase N, angiogenesis, apoptosis, metastasis 
1. INTRODUCTION 
According to the World Health Organization (WHO), cancer is the second leading cause 
of death worldwide, and was responsible for 8.8 million deaths only in 2015. Globally, nearly 
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1 in 6 deaths is due to cancer and is expected to increase approximately 70% in the next two 
decades [ l]. It is well known that cancer is neither a single nor a modem disease. Based on 
tissue and/or cell type more than 400 form of cancers are possible. The description of cancer 
was found in many ancient literatures including Egyptian "Edwin Smith" and "George Ebers" 
papyri, written between the 3000 BC [2] to 1500 BC [3]. The "Edwin Smith" papyrus refers to 
8 cases of ulcers (tumors) of the breast that were removed by cauterization with a tool called 
"the fire d1ill." It describes the disease as: "there is no treatment" [3]. A closer look into the 
fossils of over 700 dinosaurs confirmed the existence of bone cancer. Osteosarcoma (growths 
suggestive of the bone cancer) was also been noticed in the ancient human mummies in Egypt. 
The word oncos (in Greek, it means swelling) was introduced by a Greek physician Galen ( 130-
200 AD) to define tumors and accordingly the term oncology was developed. The ancient Greek 
physician Hippocrates (460-370 BC), also known as the "Father of Medicine," first 
differentiated the benign and malignant tumors by introducing the terms carcinos and 
carcinoma to describe non-ulcer forming (benign) and ulcer-forming (malignant) tumors. The 
word carcinoma in Greek stands for crab. The disease was symbolized with crab possibly 
because of its finger-like tendency to spread throughout the body. Celsus, an ancient Roman 
physician (28 BC- 50 AD) u·anslated the Greek word carcinoma into cancer (means crab in 
Latin). Since then, several hundred of years no notable progress on understanding and treatment 
of cancer was made until 1775 when Percivall Pott (a British physician) noticed that a number 
of young boys employed as chimney sweeps developed cancer of the scrotum in later life. He 
suggested the presence of something in the soot which caused cancer. Therefore, the concept 
of carcinogen (cancer causing agent) was developed [3- 6]. With the progress of research and 
consequently with better understanding the meaning of carcinoma has been modified and now-
a-days it denotes the cancer arising in epithelial cells that cover external and internal body 
smfaces; approximately 90% of all human cancers are of this type. Also many other commonly 
used terms have been developed e.g., sarcoma (cancer arising in mesenchyme-derived tissue 
(supporting tissue) which includes cancers of bone, cartilage, fat, connective tissues and 
muscle; lymphoma (cancer arising in the lymph nodes and tissues of the immune system, 
leukemia (cancer of the immature blood cells that grow in the bone marrow and tend to 
accumulate in large numbers in the bloodstream), adenoma (cancer of glandular epithelium, in 
Latin adeno means gland) etc. 
Cancer can spread in the body following two mechanisms: invasion and metastasis. 
According to National Cancer Institute, invasion denotes "the direct migration and penetration 
by cancer cells into neighb01ing tissues" whereas metastasis stands for "the ability of cancer 
cells to penetrate into lymphatic and blood vessels, circulate through the bloodstream, and then 
invade nonnal tissues elsewhere in the body'' [7]. To have a clear understanding, these two 
mechanisms can be compared with the ways fire can spread in a locality. When fire spread from 
one house to its adjacent house the process can be compared with invasion where cancer 
tissue/cells invade from one tumor to its adjacent body organ and new tumor is formed in that 
organ. The spark of fire can also spread from one burning house to a remote house by air 
(carrier). This can be compared with the migration of cancer tissue/cells carrying out by blood 
or lymph to another part of the body (for example from lung to liver) and new tumor is formed 
in that organ. Invasion and metastasis are considered as one of the hallmarks in cancer biology. 
It has been found that several enzymes are primarily responsible for proliferation, invasion and 
metastasis of the cancer cells. In this chapter, the role of a few key enzymes in cancer has been 
discussed. 
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2. RIBONUCLEOTIDE REDUCTASE (RR) 
The human body contains a specific level of Ribonucleotide reductase which is an enzyme 
that helps with the biosynthesis of deoxyribonucleoside triphosphates. This enzyme converts 
ribonucloside diphosphates to deoxyribonucleoside diphosphates for the synthesis of DNA [8]. 
Ribonucleotide reductase has three subunit proteins in which one is a large subunit and the 
others are small subunits that work differently in the body for which they have different effects 
on different cancers [7]. These subunits are known as RRMl , RRM2 and RRM2B and they 
contribute to cancer in different ways and have their own role in which some factors are still 
unclear. The three subunits affect organs such as: Lungs, colon, pancrease and the thyroid. 
There are also complications with the ribonucleotide reductase in phannaceutical levels and 
treatment because it can inhibit, block or having different affects toward the type of treatment 
being involve for the certain cancer types being involved. Like the protein subunit RRMl that 
interacts with chemotherapeutic agents like gemcitabine, and cisplatin in pancreatic cancer and 
in non-small cell lung cancer respectively. 
RRMl is known as the large subunit in which it said to behave during the cell 
transformation and tumor development as a suppressor and is still not clear in some cancers. 
The other two protein subunits are RRM2 and RRM2B that contribute to help in the repair and 
replication of DNA [8]. The small subunit RRM2 mechanism is not well-known in cancer but 
is known to have the role in cell proliferation and to repair DNA [9] . With the elevation or 
dysregulation of ribonucleotide reductase it creates a characteristic for many different types of 
cancer or can be associated with malignant transfonnation. Ribonucleotide reductase subunits 
play different roles in many organs like lungs, thyroid and colon as described as in the sequel. 
Ribonucleotide reductase actively participate in repairing DNA damage and varies in the cell 
cycle and the ribonucleotide reductase subunits help maintain the balance. For proper DNA 
repair and replication, to have stable dNTP pools otherwise it causes cell death and the subunits 
to help regulate by the RRMl and RRM2 in which the RRM l works as a regulator for S phase 
of the cell cycle transcription [8, 10]. 
2.1. Papillary Thyroid Cancer 
Thyroid cancer is a type of cancer known to be curable in many occasions. Patients with 
this disease who are being treated about 10 to 30% relapse and resist to the radio iodine 
treatment and study shows that in depth mechanistic investigation is required to develop new 
treatments. In papillary thyroid carcinoma 95.2% of the cancer tissues expressed RRMl was 
higher compare to the normal tissues showing that RMM 1 co ff elated with T-stage, lymph node 
metastasis, extra-thyroidal invasion, and TNM stage. The RRMl has been studied by using the 
high and low differentiated thyroid carcinoma cells lines called TPC-1 and SW579 respectively. 
It has been demonstrated that RRM l has promoted DNA synthesis and proliferation in both 
types of thyroid carcinoma cell lines and the high expression ofRRMl contributes to aggressive 
phenotype [8]. The expression of the RRM2 subunit in the thyroid carcinoma and the papillary 
thyroid carcinoma was high. Studies have suggested that RRM2 and RRM2B have no 
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correlation with the TNM stage, LNM stage, T stage and extra-thyroidal invasion stage. The 
RRM2 is overexpressed in other cancers also, such as gasu·ic, hepatocellular and colon cancer. 
RRMl might play role differently in thyroid cancer through ribonucleotide reductase pathway 
tlrnt still needs to be studied as well as the other protein subunits to develop effective treatment 
for thyroid carcinoma and papilla1y carcinoma. 
2.2. Colorectal Cancer 
In colorectal cancer the small subunit called RRM2 and the protein cA.t\lIP 1 (CREB l) are 
tl1e possible targets to find its treatment. The CREB 1 comes from a bZIP family which is known 
for the transcription factor that mediates the transduction between the upstream signal and 
downstream gene transcription. In colorectal cancer, the DNA repair and cell proliferation 
subunit called RRM2 becomes the promoter for CREB 1 and it works as a transcription factor 
for the subunit and enhances tumor aggressiveness. RRM2 is identified as a tumor promoter in 
many cancer cells and in colorectal cancer cells it behaves as a critical effector which makes 
CREB 1 to promote aggressiveness for the cells as well as it promotes RRM2 expression. A 
relationship between RRM2 and CRB 1 has been predicted and in reality, both of them promote 
proliferation, migration, and invasion of colorectal cancer cells [9]. Studies suggest that the 
RRMl subunit might have a potential for cancer treatment with the interaction of RRMl and 
the ubiquitous red ox protein called human thioredoxin 1. There been clinical studies for 
colorectal cancer in which human thioredoxinl and the RRl\11 subunit correlate to cancer 
malignancy stage and both produce a synergistic anti-cancer effect in the colorectal cancer 
cells. In the study of colorectal cancer, it has shown that the RRM l subunit and the human 
thioredoxinl have an interaction between each other that enhances DNA synthesis [11]. 
2.3. Lung Cancer 
There have been different studies on treatment for lung cancer and one effective treatment 
could be done by gemcitabine (Figure 1). Gemcitabine, a deoxycytidine analog, is 
phosphorylated to 5' monophosphate by the kinase called deoxycytidine and a very effective 
therapeutic agent for not only non-small cell lung cancer (NSCLC) but also for the pancreatic 
cancer [12, 13]. It has been reported that the ribonucleotide reductase subunit! and the 
messenger RNA together could be a predictor marker for the treated patients with gemcitabine 
or cisplatin. Basically, the RRM 1 is involved witl1 the repair system and synthesis of 
deoxyribonucleic acid in which it participates in DNA strand of incision and damage 
recognition [12]. Studies have shown that the subunit RRMl may have effect towards the 
gemcitabine response because the subunit might be the intracellular target for this agent [13]. 
Two non- small cell cancer cell lines (H356-G200 and H460-G400) were selected for this study 
and the activity of the protein RRMl was analyzed even though with its high levels the 
ribonucleotide reductase did not increase in one of the cell lines (H356-G200) and on cloning 
the encoded RRM 1 from these cells did not show any mutation. It was seen that 48% of the 
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lung tumors being studied had a loss ofheterozygosity of the chromosomal region that had the 
ribonucleotide reductase subunit Ml in this case saying that it can act as a tumor suppressor 
[13]. 
f: 




Figure 1. Strncture of ribonucleotide reductase inhibitors: Gemcitabine and Cis-platin. 
2.4. Pancreatic Cancer 
Pancreatic cancer is still known as one of the lethal types of solid tumor due to its high 
resistance toward chemotherapeutics. Pancreatic cancer is one of the leading causes of cancer-
related death for both men and women and is the only major cancer with a 5-year relative 
survival rate in the single digits, at just 7. 7% [ 15]. While overall can cer incidence and death 
rates are declining, the incidence and death rates for pancreatic cancer are increasing [ 16]. It is 
a matter of serious concern that pancreatic cancer is projected to move past colorectal cancer 
to become the 2nd leading cause of cancer-related death in the United States around 2020 [ 17]. 
The justifications behind this estimation are: (i) in comparison to other cancers, pancreatic 
cancer can progress very quickly from stage I (localized within the pancreas) to stage IV 
(metastatic disease) in an average of 1.3 years; (ii) cunently, there are no proven biomarkers, 
or clues detectable in the blood or other bodily fluids th at could indicate the presence of a 
pancreatic tumor; (iii) only fewer than 20% of pancreatic cancer cases are diagnosed th at meet 
the criteria for surgical intervention (often the Whipple procedure) although the disease recurs 
in approximately 80% of these surgical patients; (iv) for non-surgical patients (not suitable for 
surgery), chemotherapy (sometimes along with radiation) is typically offered but is not 
considered curative at all (v) around 95% of pancreatic tumors are driven by mutations in 
KRAS gene, which signifies a very aggressive and treatment-resistant tumor. Mutated KRAS 
has been dubbed "undmggable." Both in pancreatic and lung cancers, the subunit RRMl 
overexpression has poor survival than with low levels ofRRMl after the gemcitabine treatment 
which makes the level t.o be become an indicator for gem-resistance. There are various 
metabolic enzymes that supposed to play significant role in drng-resistance that include, but 
are not limited to, ribonucleotide reductase Ml subunit, deoxycyridine kinase, cytidine 
deaminase and the ribonucleotide reductase M2 subunit [14]. In the human pancreatic cancer 
cell lines the levels of RRMl are associated with the chemotherapeutic agent (gemcitabine) in 
five pancreatic cancer cells and the agent with the patients that had low RRMl was more 
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effective. This showed that patients with low expression ofRRMl can live longer than those 
having overexpression ofRRM l [14]. It has been suggested that ribonucleotide reductase can 
help in reducing the antitumor effect on gemcitabine since the ribonucleotide reductase 
increases the dNTP which is referred to deoxynucleoside triphosphates pool in the cells that 
produces a decrease of the deoxy ribonucleotide analogues like the triphosphorylated 
gemcitabine into DNA. The RMMl protein subunit of ribonucleotide reductase plays different 
roles in cancer but in pancreatic cancer it's a target for gemcitabine and the inhibition of the 
RRl\111 reduces sensitivity of gemcitabine [ 18]. 
3. THYMIDYLATE S YNTHASE (TS) 
The enzyme Thymidylate Synthase (TS) produces an essential precursor used in DNA 
replication. By inhibiting the action of this enzyme, the production of deoxythymidine 
monophosphate ceases. Not only does this disrupt the production of this necessary precursor, 
but TS inhibition subsequently intenupts the DNA replication process altogether. This 
intenuption of DNA replication in rum leads to apoptosis or programmed cell death. It is a 
chain of events that makes Thymidylate Synthase an important point of study in anticancer 
research. By inhibiting DNA biosynthesis and causing cell death, the uncontrolled cellular 
division that is seen in many types of cancer can be slowed down. Thymidylate Synthase 
inhibitor drugs and prodrugs are commonly used for this purpose. Although this type of 
treatment is relatively effective against many types of cancer, including colorectal, gastric, 
pancreatic, and ovarian cancers, research is still being unde1taken to detennine whether it can 
be effectively used against other types of cancer. 
Thymidylate Synthase is a key enzyme in the synthesis of 2'-deoxythymidine-5'-
monophosphate, an essential precursor for DNA biosynthesis [19] . The progression of a cell 
through the cell cycle checkpoints ensures that the subsequent generation of cells have the 
components necessary to preserve homeostasis and developmental morphogenesis [20]. This is 
trne for both carcinogenic and non-carcinogenic cell lineages. With this being the case, the 
activity of an enzyme, in this instance TS, which produces an essential precursor for DNA 
biosynthesis has significant and direct implications on the completion of the S Phase in the cell 
cycle. For example, total inhibition of Thymidylate Synthase would interfere with the 
progression of tl1e cell cycle by disrupting the synthesis of 2 ' -deoxythymidine-5 ' -
monophosphate (dTMP). It is well known that progression of the cell cycle and control of 
apoptosis (programmed cell death) are intricately linked processes [21, 22]. Research has 
confirmed that the inhibition of TS leads to the cessation of DNA replication and thymineless 
death of proliferating cells, which renders the enzyme as an attractive target for cancer 
chemotherapy [23]. However, in order to get a better understanding on why TS inhibition 
causes DNA replication to halt and the cell to die a thymineless death, it is necessary to 
understand the enzyme's strncture, tl1e mechanism through which the enzyme functions, as well 
as its place in the cell cycle. 
Thymidylate Synthase is an obligato1y homodimer which fonns a complex with dUMP (2'-
deoxyuridine-5 '-monophosphate) and a THF (tetrahydrofolate) cofactor [23]. TS catalyzes the 
reductive methylation of 2'-deoxyuridine-5 '-monophosphate (dUMP) by transfer of a 
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methylene group from a cofactor to generate deoxythymidine-5'-monophosphate dTMP [24]. 
In this process, the enzyme TS takes dUMP, and uses 5,10-methylenetetrahydrofolate as a 
cofactor to donate a methyl group, forming dTMP. It should be noted that although dTMP is a 
molecule, found in the nucleotides which compose the strands of DNA, produced by TS is not 
immediately available for use in the process of DNA biosynthesis. The dTMP entity is further 
phosphorylated to the triphosphate state ( dTTP), which is a direct precursor for DNA synthesis. 
By blocking the synthesis of2 '-deoxythymidine-5'-monophosphate, there can be no formation 
of 2'-deoxythymidine-5'-triphosphate, the nucleotide which is used to incorporate a thymine 
nitrogenous base into a newly forming DNA molecule during S Phase. As it has been previously 
mentioned that the inhibition of TS leads to the cessation of DNA replication and thymineless 
death of proliferating cells, which renders the enzyme an attractive target for cancer 
chemotherapy [23]. 
Furthennore, TS is the rate-limiting enzyme in the de novo synthesis of deoxythymidine 
monophosphate from deoxyuridine monophosphate [25]. The interruption of DNA replication 
blocks progress through the cell cycle which is thought to be intimately linked to control of 
apoptosis [20]. Taken together, the inhibition of TS indirectly blocks the replication of DNA 
which in tum leads to apoptosis. Therefore, this enzyme is considered an attractive target for 
cancer chemotherapy. When viewed from a cettain perspective, inhibition of thymidylate 
synthase in cancer cells leads to the death of the cancer cells. 
These nitrogenous bases, also known as organic bases (Figure 2), bind in a specific and 
complementary way. One purine will bind to one pyrimidine. In both RNA and DNA, guanine 
(a purine) binds to cytosine (a pyrimidine) via three intermolecular hydrogen bonds. Similarly, 
adenine (a purine) will bind with either thymine in DNA (a pyrimidine) or uracil in RNA (a 
pyrimidine) through two intermolecular hydrogen bonds. Schematic depictions of the 
interactions between adenine hydrogen bonding with thymine, as well as adenine hydrogen 
bonding with uracil are depicted in Figure 3. 
NH2 0 
N~ N HN:XN';) lL /, ~ 






Figure 2. Purines and pyrimidines: the 'organic bases.' 
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Figure 3. Pictorial representation of H-bonding between Adenine-Thymine, Adenine-Uracil and 
Guanine-Cytosine. 
Each of strand of DNA is a polymer composed of nucleotide monomers, which are joined 
together to form the chromosomes we see, noting that the longest chromosome is - 250 million 
nucleotides in length [26]. It should be noted that each of these nucleotides are composed of 
three primary structural elements: 
1. 5-Carbon sugar molecule (ribose/deoxyribose for RNA/DNA, respectively) 
2. Phosphate group bound to the 5' carbon of the sugar molecule 
3. Nitrogenous base bound to the l ' carbon of the sugar molecule 
Thymidine nucleotide is pictured in Figure 4. It should be noted that although dTMP is the 
final molecule incorporated into DNA, dTTP is its precursor molecule. The two extra phosphate 
groups on dTTP a.re hydrolyzed to provide the energy needed to incorporate dTMP into the 
newly forming strand of DNA. 
OH H 
Figure 4. Deoxythymidine-5'-phosphate ( dTMP, thymidylic acid). 
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5-Fulorouracil 
(5-FU) 
Figure 5. Thymidylate Synthase inhibitor as anticancer drugs. 
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The 5' sugar and phosphate components are important in maintaining the strnctural 
integrity of DNA, and they compose its "backbone" [25] but it is the latter of these three 
structural components, the nitrogenous bases that is the most critical to the current discussion. 
There are two types of nitrogenous bases that constitute the nucleotide monomers found in 
DNA: The purines and the pyrimidines (Figure 2). For the purposes of this discussion, it is 
important to emphasize the structures of uracil and thymine, noting that they are identical with 
the exception of a methyl group at the 5 position. 
During the replication of DNA, the enzyme DNA polymerase takes advantage of the 
complementarity exhibited by the nucleotides which comprise the genetic code. By using one 
of the double helix's strands as a template, DNA polymerase enzymes add nucleotides in a 
complememary manner, binding guanine with cytosine, and adenine with thymine. This 
process is repeated um.ii two copies of the genome have been created from one initial copy. It 
should be noted that an event which damages the DNA during the course of genetic replication 
could result in DNA damage response and apoptosis [27]. 
Following the DNA biosynthesis in the S Phase, the cell enters a final growth phase to 
prepare for cellular division. Accordingly, the purpose of this discussion emphasizes on the S 
phase. The S Phase is where the action of TS becomes a factor in anticancer research. Although 
it does not directly participate in DNA biosynthesis, TS's activity has a direct impact on the 
cell's ability to replicate a copy of the genome, which in turn affects the fate of the cell. 
Several Thymidylate Synthase inhibitor anticancer drugs like 5-fluorouracil and raltitrexed 
as well as tl1e prodrng capecitabine have been approved by the FDA (Figure 5). The drug 5-
fluorouracil (5-FU) is structurally similar to the pyrimidine base uracil. The similarity in 
composition allows 5-FU to act as a substrate in the same metabolic pathway as uracil, and 
after its conversion to 5-fluorodeoxyuridine monophosphate, 5-FU inhibits the enzyme 
thymidylate synthase, ultimately inhibiting DNA synthesis [28]. As previously discussed, this 
inhibition leads to apoptosis. It should be noted that the mechanism of 5-FU's cytotoxic 
activity, however, it appears insufficient to explain all of the pharmacological effectiveness of 
5-FU and further investigations are required. The prodrug capecitabine follows a similar 
fluoropyrimidine based mechanism of inhibition [29]. In target cells it is converted to 5'-deoxy-
5-fluorouridine in a three-step sequential enzymatic pathway and eventually it is convened to 
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5-FU. Once capecitabine is transformed to 5-fluorouracil, the same mechanism of action 
detailed above was observed. Although, capecitabine is transformed into 5-FU, this pyrimidine 
analog method ofthymidylate synthase inhibition is not the only technique available to stop TS 
activity. The drng raltitrexed takes advantage of the fact that a folate cofactor is needed for TS 
to function [30]. Raltitrexed acts as an antifolate molecule which inhibits the activity of TS. 
This therapeutic effect is imparted by raltitrexed competitively binding TS in an irreversible 
manner. This disallows the enzyme to bind its necessary cofactor, and DNA biosynthesis is 
stopped. 
These drngs have proven to be effective in inhibiting TS activity, but it should be noted 
that one meta-analysis that investigated 2,442 (gastric cancer) patients in 25 studies observed 
that response rates for FUC (fluoropyrimidine based chemotherapy) were significantly lower 
in patients with high TS activity than in those with low expression [31]. This indicates that 
although the drngs can effectively inhibit TS activity, a higher level of TS expression may make 
it more difficult to combat cancer using this technique. Furthennore, the studies which 
composed the meta-analysis had va1ying results, so the mechanism between levels of 
thymidylate synthase expression vs. treatment with drngs that inhibit TS is still unclear. 
Despite being very effective in certain types of cancer, particularly colorectal and gastric, 
research is still being undertaken to determine the advantage of using thymidylate synthase 
inhibitors against many types of cancer known to the modem medical community. 
4. TOPOISOMERASE II 
DNA topoisomerase II is a validated target for chemotherapeutic agents because disruption 
of this enzyme damages the DNA. DNA topoisomerases are enzymes that regulate the winding 
of DNA during replication and transcription. When DNA is replicating or being transcripted, it 
wounds tightly ahead of the replication fork. Topoisomerases keep the double helix from 
becoming too tightly wound by binding to the double-stranded DNA and cutting the phosphate 
backbones of the strands. By cutting the backbones of the DNA strands, they can be untangled 
and prevented from winding too tightly. At the end of the process, the DNA strand is resealed. 
The name topoisomerase comes from the fact that as the enzyme works on the DNA, the 
untangled and tangled strands are isomers that only differ in their topology. Therefore, 
topoisomerases are isomerase enzymes that only change the topology of the DNA [32]. There 
are two types of DNA topoisomerases in mammals: topoisomerase I and topoisomerase II [33] 
in which topoisomerase II enzyme is used in regulating DNA super helicity. Unlike 
topoisomerase I, topoisomerase II requires the binding of ATP and hydrolysis in order to 
function correctly. Topoisomerase II functions by cutting and opening the duplex of one DNA 
strand, stringing a second duplex through the passage it created, and then repairing the damage 
[34]. 
DNA topoisomerase II has been using as a target for a variety of anticancer drugs such as 
anthracenediones, anthracyclines, amsacrines, ellipticines, and non-intercalating etoposides 
[35, 36]. The structure of four anthracyclines (doxorubicin, daunorubicin, idarubicin, and 
epirnbicin are shown in Figure 6. In order for these drugs to work effectively, they must be able 
to disrupt at least one step of the catalytic cycle of DNA topoisomerase II. Drugs that can 
stabilize the topoisomerase II complex are known as topoisomerase II poisons and other drugs 
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that disrupt any steps of the catalytic cycle are known as catalytic inhibitors. The most used 
"topoisomerase inhibitors" are actually topoisomerase II poisons, which are utilized for their 
antitumor activities [37] . Although they all share similar mechanisms as to how they disrupt 
the function of DNA topoisomerase II, they have different pharmacological and 
pharmacodynamics characteristics. There are also slight nuances as to the toxicological effects 
each of these drugs have, with the anthracyclines exhibit higher toxicity whereas elliticine and 
mitoxantrone showed reduced toxicity (Figure 7). Etoposide is a derivative of podophyllotoxin, 
a drug used for the treatment. of genital warts and molluscum contagiosum. Historically, 
podophyllotoxins were used to treat cancers of the skin in the 19th century [38]. After clinical 
studies, podophyllotoxins and some of its derivatives showed promising antineoplastic activity. 
Despite their promise as antineoplastic agents, podophyllotoxins and their derivatives showed 
toxicity toward normal cells/tissues. Researchers began synthesizing more podophyllotoxin 
derivatives in order to find one that did not have so much toxicity and came across 4 ' -
demethylepipodophyllin benzylidene glucoside (DEPBG). Two more analogues of DEPBG 
that showed even more promising antineoplastic activity, etoposide and teniposide, were then 
developed [39]. Etoposide is used to treat various cancers as a topoisomerase II inhibitor. These 
cancers include leukemia, lung cancer, lymphoma, nemoblastoma, ovarian cancer, and 
testicular cancer. Often, it is administered in combination with other chemotherapeutic agents 
and even used as a conditioning agent to ready a patient for a bone man-ow transplant. Although 
there is no clear mechanism of action as to how etoposide damages DNA, it is hypothesized 
that the drng interferes with the cleaving and resealing of the topoisomerase II' s function by 
forming a stable protein-ligand cleavable complex [ 40]. So far, caspases, protease enzymes that 
play critical roles in cell apoptosis, have been shown to be a link between etoposide's activity 
and the mitochondrial apoptosis pathway, particularly caspase 2 [41]. By activating caspase 2, 
caspase 8 is also activated, which damages the mitochondria and causes the successive 
downstream activation of caspase 9 and 3 [42]. Mutations in the caspases has shown to affect 
etoposide's ability to work. A lack of caspase 3 in cells causes it to be resistant to etoposide 
[I 7]. The TNF- related apoptosis-inducing ligand (TRAIL), a ligand that causes apoptosis, also 
changes how caspases are expressed when activated by etoposide. Other proteins, such as p53, 
c-Myc, and Baff, which control the cell-cycle have also been shown to be important in 
etoposide-activated apoptosis [42]. Multiple mechanisms exist that make tumors resistant to 
etoposides. These mechanisms include a mutation at ser-1106 in topoisomerase II that annuls 
the enzyme's phospho1ylation and reduces the effectiveness of etoposide, rapid repair of DNA 
breaks, functioning FLT3, and possessing a multidrug resistance (MDR) phenotype [ 43-45]. 
To make etoposide work on MDR resistant tumors, it must be turned into a prodrug which can 
create analogs of etoposide. 
As stated before, despite its use as an anticancer drug, etoposide has some toxicity (side 
effects). Common side effects of administering etoposide include nausea, vomiting, bone 
man-ow suppression, and alopecia. When administered in high doses, etoposide can cause fever, 
chills, liver toxicity, anal cavity irritation, and Palmar-planter eruptions. The World Health 
Organization (WHO) has also classified etoposide as a carcinogenic agent because current 
clinical evidence suggests that administration of etoposide can eventually cause acute 
myelogenous leukemia [ 46]. Leukemia caused by etoposide administration occurs 
approximately 2 to 3 years after treatment. This can be caused by the translocation of the mixed-
lineage leukemia (MLL) gene which can result from the activation of the caspases. Toxicity 
was mostly observed in patients who kept the etoposide concentration above l. 7 µM for over 
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8 hours, which suggests that drug plasma concentration must be kept at a sufficient level to 
produce therapeutic effects, but that extended high concentrations of plasma etoposide causes 
greater toxicity [49]. About one one-third of etoposide administered through I.V. is excreted 
through urine and less than 2% of intact drug is eliminated into bile [50]. Only 6-8% of 
etoposide does not bound to plasma proteins, making it highly bound when administered. 
Disorders that affect how much protein binding there is or decrease the amount of albumin in 
the bloodstream will cause an increase of the pharmacological effect of etoposide since free 
drug is still biologically active. This could lead to an increase in unwanted side effects. There 
are relatively few known drug interactions with etoposide. There are no substantial interactions 
with cisplatin and carboplatin (platinum agents) [ 51] and grapefruit juice, which can inhibit the 
cytochrome P450 metabolism, does not affect the kinetics of etoposide [52]. But, related use of 
prednisone can induce etoposide excretion which may be caused by the induction of P-
glycoprotein (PgP) [53]. 
A closely related analogue of etoposide in teniposide (Figure 7). It was approved for 
medical use 10 years after etoposide was approved. The drug has mostly been used to treat 
child leukemias and lymphomas and CNS malignancies. It is administered by I.V. and if it leaks 
under the skin, burns the patient. Like etoposide, it can be used in conjunction with other 
anticancer drugs. Its mechanism of action is similar to etoposide in that it damages the DNA 
by forming cleavable complexes with topoisomerase II. Its toxicity effects are also similar to 
etoposide by causing nausea, vomiting, bone ma1Tow suppression, and alopecia. However, 
hypersensitivity happens more often with infusions ofteniposide than etoposide. It is also more 
potent at killing malignant cells than etoposide, which may be caused by better cellular uptake. 
It has less water solubility, renal clearance, binds tighter to plasma proteins, has a longer half-
life, and a larger biliary clearance than that of etoposide [54 ]. 
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Figure 6. FDA approved anthracyclines as topoisomerase II inhibitors. 
Anthracyclines are a set of drugs that are used as chemotherapeutic agents. They are usually 
extracted from the bacteria Streptomyces and Streptomyces peucetius var. caesius. This class 
of drugs are effective against more types of cancer than any other anticancer agents and only 
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few cancers, such as colon cancer, are insensitive to these drugs, making them one of the most 
successful chemotherapeutic treatments ever done. Idarubicin, epirubicin, doxorubicin, and 
daunorubicin are anthracyclines currently approved for medicinal use as topoisomerase II 
inhibitors. Anthracyclines are used to treat an ass01irnent of neoplastic cancers such as 
lymphoma, breast cancer, Kaposi 's sarcoma, Ewing's sarcoma, leukemia, and ovarian cancer. 
Of all the anthracyclines, doxorubicin is the most commonly used drug. There have been 
attempts to create an analog similar to doxorubicin, but they have failed to reproduce its potency 
against solid tumors. The epimer of doxorubicin, Epirubicin, has similar activity and is mainly 
used to treat breast cancer [55] . Daunorubicin, in contrast, has little activity against solid 
tumors, but it is an important medicine against acute leukemia [56]. The analogue of 
daunorubicin is idambicin and it is mainly used for acute myeloid leukemia (AML) treatment. 
There has been evidence that idarubicin has a survival advantage over daunorubicin, but the 
effects are minimal. However, it has significant bioavailability [ 57]. There are four mechanisms 
in which anthracyclines work. One is that they inhibit the synthesis of RNA and DNA by 
intercalating the base pairs of the DNA/RNA strand, which causes the prevention of cancer 
cells from rapidly replicating. The second mechanism is the generation of free oxygen radicals 
mediated by iron that damage components of the tumor such as its proteins, cell membrane, 
and DNA [58]. The third mechanism involves histone eviction from chromatin that disrupts the 
epigenome, transcriptome, and DNA damage response [59]. Finally, the mechanism most 
relevant for this chapter, anthracyclines can inhibit topoisomerase II in the same way that 
etoposide was previously described [60]. 
Myelosuppression is the dose-limiting toxicity of anthracyclines. Like etoposides, side 
effects include nausea, alopecia, vomiting, and mucositis. Administering anthracyclines can 
also cause severe tissue reactions if leakage occurs under the skin during intravenous infusion. 
The wounds can degrade further over a period of weeks, heal slowly, and may even require 
skin grafting. Cardiotoxicity is the most serious side effect that is associated with treatment 
with anthracyclines. Three types of cardiotoxicity have been observed based on how soon 
symptoms appear. Immediately after infusion, there is acute cardiotoxicity that can include 
arrhythmias and pericarditis. Months to years after treatment with anthracyclines, late-onset 
cardiomyopathy can appear. If children are treated with anthracyclines, subclinical 
cardiotoxicity can appear when the children become adolescents or adults [ 61]. This 
cardiotoxicity is thought to be a result of the production of free radicals that involve iron-
doxorubicin complexes that damage the membranes of cardiac cells [62]. In respective studies, 
the total dose and schedule of anthracycline that was administered with a bolus was found to 
cause a greater chance of heart failure than continuous infusion [ 63]. There have been several 
attempts to remedy anthracycline's propensity to cause cardiotoxicity. One strategy includes 
administering dexrazoxane, which can presumably prevents the iron-catalyzed free radicals 
from damaging cardiac cell membranes because it is an iron-chelating agent. Several studies 
have shown that administering dexrazoxane alongside anthracyclines can protect the heart 
without affection the anthracycline's antineoplastic abilities [64]. Another strategy included 
encapsulating the anthracycline in liposomes to prolong its half-life and try to make it 
accumulate in tumor tissue instead of cardiac tissue. Cardiotoxicity was found to be reduced 
from 21 to 6% in patients with metastatic breast cancer when liposomal doxorubicin was 
administered compared to straight doxorubicin [65]. It is imperative that the cardiotoxicity of 
anthracyclines be minimized because once developed, it is irreversible and may advance into 
congestive heart failure even after treatment [ 66]. 
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The anthracyclines are metabolized into 13-dihydro (alcohol) derivatives that are more 
toxic than the original compounds [ 67]. As mentioned before, encapsulating the drug with 
liposomes prolongs its half-life and can also change its pharmacodynamics characteristics. 
These deviations are based on the kinds of lipids used in the formulation of the liposome. There 
are two FDA-approved doxorubicin liposomal formulations. They are doxil and myocet. Doxil 
uses pegylated lipids in its formulation while Myocet uses phosphatidylcholine and cholesterol. 
Doxil is a slow acting drug, only releasing less than 10% of its doxorubicin within a day. This 
makes its half-life to be about 45-90 hours. It.s toxicity effects also change, causing palmar-
plantar e1ythrodysesthesia and mucositis. Myocet is a faster acting drug than Doxil. It releases 
half of the doxorubicin within an hour. Myocet's toxicity effects are myelosuppression and 
mucositis [68]. 
Mitoxantrone is the only representative of its class, anthacendiones, which is approved for 
medicinal use. (Figure 7). Anthacendiones are usally compounds that are used in the textile 
industry to create dyes, or in the pulp industry, or even as bird repellant. Unlike anthracyclines, 
it does not have the ability to fo1m the cardiotoxic free radicals [69]. Like most topoisomerase 
II poisons, mitoxantrone binds to the enzyme and forms a stable, cleavable complex that causes 
the DNA strands to break. This causes apoptosis, killing the cell [70]. There are several ways 
that tumors can become resistant to mitoxantrone. Several mechanisms include a change in 
topoisomerase II activity, less intracellular drug accumulation, an increase in glucuronidation, 
and a change in nuclear/cytoplasmic distribution of the drug [71]. Mitoxanrrone has a large 
volume of distribution, 1000-4000 1/.1112, and binds to protein tightly, 78% [72]. Its main 
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The usual cancers treated with mitoxantrone are prostate cancer, leukemia, lymphoma, and 
breast cancer. Since there is overall less toxicity with mitoxantrone compared to doxorubicin, 
it is used for patients who may be sensitive to the toxic effects of doxorubicin. Mitoxantrone 
has shown no advantage over any of the anthracyclines. Mitoxantrone can also be administered 
in conjunction with prednisone to delay disease and improve the patient's quality oflife without 
affecting survival length. 
Ellipticine is a natural, simple alkaloid that is a known DNA topoisomerase II inhibitor. It 
has shown to have therapeutic effects against a variety of cancers. There is a strong interest in 
ellipticene and its derivatives because they have a high efficiency against a variety of cancers, 
with less effects, and a lack of hematologic and hepatic toxicity [74]. One negative aspect about 
ellipticine is its propensity to mutate. Ellipticine is also mutagenic to Salmonella typhimurim, 
Neurospora crassa, bacteriophage T4, and mammalian cells. The exact mechanism in which 
ellipticine causes apoptosis is unknown. However, it is theorized that DNA damage can be 
caused by either the interaction with DNA topoisomerase II or the intercalation into DNA [75]. 
A further study has shown that ellipticine can stimulate a topoisomerase II-mediated DNA 
breakage. The study consisted of using a yeast genetic system to determine that the target for 
ellipticine was indeed topoisomerase II. The study provided a model that seemed to indicate 
that a topoisomerase II-ellipticine-DNA complex is formed when the drug initially binds to the 
enzyme or the DNA itself [76]. 
5. INTERLEUKINS 
Interleukins a.re low molecular weight cytokines that a.re secreted by white blood cells 
(leukocytes) and a.re one of the most essential to the immune system response by eliminating 
wounds, such as: infections, foreign bodies and other substances in order to begin the healing 
process. Some majorly important interleukins would be IL-1 , 2, 3, and 6, which signal the 
attraction of phagocytes and other correcting cells to the sight of the wound or infection. The 
major importance of interleukins is the ability to develop new blood vessels, which is a process 
called angiogenesis. Interleukins have the ability to inhibit or promote the ability to create new 
blood vessels. Interleukin-I (IL-1) contains pro inflammatory cytokines, which function to 
protect inflammatory responses. IL-6 has been known to induce vascular endothelial growth 
factor (VEGF) expression, which then enables the promotion of the creation of new vessels 
whereas IL-3 supports the growth and differentiation of bone marrow stem cell. Interleukin-2 
is produced exclusively by T-lymphocytes by the activation of antigen and mitogens. Human. 
To induce biological activities, interleukin-2 binds to a fixed receptor on the surface of 
extremely delicate cells. The fixed receptor complex consists of three membrane-spanning 
polypeptide chains (alpha, beta, gamma chains). The alpha chain binds interleukin-2 with low 
affinity, while gamma subunit does not interact directly. Alpha and beta chains play a role in 
intracellular signaling and signal transduction, respectively. However, the role of gamma chain 
is still unclear but critical. IL-2 enhances antibody production and secretion and it has the ability 
to stimulate the growth and differentiation of natural killer cells which then form lymphokine-
activated killer cells, leading to its ability to eliminate tumor cells or virally infected cells 
directly. Treatments to cancer immunotherapy have therefore been formulated to increase the 
survival rate of patients, many involving the utilization ofinterleukin-2 as the primary immune-
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stimulant, including stimulated natural killer cells, LAK (lymphokine-activated killer) cells 
activated in vitro, and stimulation of cytotoxic T-cells, which promote tumor regression. In the 
T cells stimulation, interleukin-2 increases the number ofT-cells, then activates and boosts cell 
production. The specific T-cells would therefore inhibit cancers. The administrations of a 
significantly high doses of interleukin-2 by itself could initiate a similar response, but will 
sustain side effects. The ability of interleukin-2 to trigger the stimulation of T-cells is essential 
in the treatment of infectious diseases. Administrations of interleukin-2 can induce side effects, 
such as cardiovascular, hepatic or pulmonary complications. The side effects may be produced 
not only directly by interleukin-2, but also by plenty of other additional cytokines whose 
synthesis is amplified by IL-2 administration. The additional cytokines are interleukin-3, 4, 5, 
6, tumor necrosis factor, and interferon-y. Many medical conditions are caused by the immune 
system itself. A treatment strategy to fight cancer might include giving high dose interleukin 2 
or IL-2 through and intravenous IV infusion. IL-2 is a substance that tells the immune system 
to fight against ailments. T-cells clutch on to a few cancer-causing proteins and become 
activated and cause the cancer cells to break apart. Receiving IL-2 through an IV allows it to 
move throughout the body and act on cancer cells that may have spread. High dose ofIL-2 is a 
standard tTeatment that was approved to treat metastatic melanoma and metastatic kidney 
cancer. High dose IL-2 is given to patients with advanced melanoma or those with metastatic 
kidney cancer who cannot be treated with surge1y. The role of interleukin 2 therapy made a big 
splash when it was introduced for kidney cancer was approved by the FDA for this indication 
back in 1992. Since then there's been a lot of debate whether or not IL-2 or interleukin 2 
represent the most ideal therapy for patients with metastatic or distantly spread kidney cancer 
although this therapy may cause severe cardiac and lung toxicities [77]. 
6. CELL SERVIV AL PROTEINS 
Cells live in competition with each other; healthy cells embrace tissue while competing 
with those cells that m·e older/weaker. Once the "healthy" cells seize they would get rid of the 
older cells by a process called apoprosis. Apoptosis is good in the sense that it gets rid of 
unwanted cells but has also been linked in developing certain cancers. The body is built like a 
large machine when it feels that it has things that are old or that it does not need it will "upgrade" 
to get rid of the old things to bring new things in such as regulating stem cells, and tissue re-
population. The cell survival proteins in the human body play import.ant role in cell 
survival/death programs, proliferation and the elimination of damaged cells. When cells feel, 
they are being " invaded" they tly and figure out the cause of it, when they do not seem to find 
the root of the problem they activate different mechanisms to get rid of whatever is out of the 
nonn. When they still feel threatened, they go to activate the cell death programs or cell death 
signaling pathways to remove the damaged cells. There are two types of cell injury, that is 
reversible cell injury which is harm done to the cell that can be reversed once the stress has 
been relieved. Irreversible cell injury, which causes the cell to die or go through cell suicide. 
Certain things that affect the cell positively or negatively can be stress induced leading the cell 
suicide. It can be good in the sense that it is getting rid of the infected cells, cancer cells, and 
Key En:ymes in Cancer 373 
damaged cells. Cell death programs must be kept in check since unregulated cell death is linked 
with the production of different diseases. There are various ways of getting rid of damaged 
cells, the cell death program is broken up into various components such as apoptosis (type 1), 
which causes shrinkage. In the human body, there are about 50-70 billion cells th at die each 
day. It is a normal process during embryological development and a normal process during the 
development of our immune system. 
As it has been stated before, cancer is caused by the uncontrolled proliferation of cells, 
cancer cells are hungry in order to meet their demand for the nutrients and cellular building 
blocks that enable them to grow and divide their metabolism rapidly. New insights into these 
processes have sparked interest in developing drugs that target the unique metabolic 
characteristics of cancer cells. Such drugs have the potential to treat cancers arising from many 
different tissues, while leaving normal cells mostly unaffected. The altered metabolism of 
cancer cells includes an increased uptake of nutrients such as glucose and glutamine. They also 
start to metabolize glucose in a slightly different way, a phenomenon called the Warburg effect. 
In a ll cells, glucose is broken down in several steps to pyruvate. In nonnal cells most of the 
pyruvate enters the citric acid cycle in the mitochondria, which effectively acts as the energy 
factories of the cell. In this way, most of the glucose that is taken up is completely oxidized to 
carbon dioxide. In the 1920's Otto Warburg discovered that cancer cells unlike healthy cells 
metabolize most of their glucose using biochemical pathways that do not require oxygen 
regardless of whether oxygen is available. Excess glucose is taken up and like in nonnal cells 
broken down to pyruvate, however instead of entering the citric acid cycle most of the pyruvate 
is converted to lactate, which is secreted from the cell. It is still controversial why tumor cells 
employ this relatively ineffective way of extracting energy from glucose. One theo1y is that the 
process reflects a metabolic program that cells use to conve1i nutrients into the building blocks 
of macromolecules. Cells can be viewed as molecular factories; glycolysis is not the only aspect 
of the cells metabolism that is altered [78]. Cancer cells undergo a general shift from catabolic 
to anabolic metabolism in order to produce the greatly increased amounts of proteins, nucleic 
acids and liquids they need to supp01i their high rates of proliferation. Cancer cells also take up 
amino acids, amongst these, glutamine is of particular importance, it acts as a key source of 
nitrogen which is required for nucleotide and new amino acid synthesis. In some cancer cells 
glutamine also acts as a critical source of carbon, which is required for replenishing the 
components of the citric acid cycle. Many anti-cancer drugs on the market have metabolic 
targets in the cells although for a large proportion of them the metabolic target was only 
recognized long after the drug was developed. For example, the widely used chemotherapy 
drugs 5-flurouracil and gemcitabine interfere with DNA synthesis. Today there are many 
approaches in development that a im to target different aspects of cancer cell metabolism. The 
possibility of exploring of blocking glutamine to inte1rupt the supply of carbon and nitrogen. 
They are also considering other enzyme targets that might limit the use of nutrients to make 
key building blocks. Some strategies are a imed at interfering with the high rates of glucose 
metabolism and lactate secretion as described by Otto Warburg. Anticancer approaches 
targeting tumor metabolism faced many challenges a major one is finding the therapeutic 
window to prevent toxicity to no1111al tissues. However, it has become clear that the genetic 
changes associated with cancer can create addictions to specific metabolic pathways, which can 
374 Debasish Bandyopadhyay, Gabriel Lope=, Stephanie Cantu et al. 
be therapeutically exploited. Moreover, cancer cells can be more sensitive to metabolic alarms 
than nonnal cells due to the loss of cell cycle checkpoints. A better understanding of how 
metabolism is altered in specific genetic context that lead to cancer will help identify enzymes 
or combination of enzymes to target for intervention and hopefully allow the introduction of 
more effective anti-cancer drugs. Cancer cells form blood vessels around them to receive 
oxygen and nutrients. However, cancerous blood vessels are structurally and functionally 
abnormal, so blood or oxygen can flow poorly compared to normal blood vessels, which 
hampers the effects of anticancer drugs. It has also been rep01ied that that normalizing the blood 
vessels increased the oxygen supply in cancerous tissues and slowed the growth of cancer. The 
drug efficacy is enhanced by the delive1y and effectiveness of existing drugs, giving a lower 
does is sufficient for treatment. For example, cis-platin is an important anti-cancer drng which 
is an in credibly useful complex, it is used to treat various cancers. In particular, it is very useful 
that it has given a_greater than 90% survival rate in testicular cancer. The functions of cis-platin 
bonds to DNA and it bonds to the nitrogen on guanine one of the nucleotides in DNA. If the 
lone pairs of electrons on the nitrogen that allows nitrogen to fonn date of covalent or 
coordinate bonds with the cis-platin complex that fo1ms bonds with the DNA nucleotides and 
it is actually a ligand substitution reaction, the guanine is substituted for the chloride ligands, 
since guanine is a better ligand to serve this purpose. Cis-platin is bound to our DNA and it 
distorts the DNA and prevents the effective replication cis-platin prevents the cells from 
multiplying and this DNA from copying and that's what allows it to act as an effective anti-
cancer drug, and cancer cells multiply ve1y fast which is what allows them to be super 
dangerous on the tumors to grow and if the drug can prevent the application it can be useful in 
the treatment of different cancers [78, 79]. 
7. AMINOPEPTIDASE N 
Aminopeptidase N (APN, also known as CD-13) is a widely expressed type II 
trnnsmembrane protease that is heavily correlated with various solid and hematological 
malignancies in humans. APN degrades preferentially proteins and peptides with a N-tenninal 
neutral amino acid. It is a tumor marker that is overly expressed on the cell surface of almost 
all major tumor fonns including skin, ovary, lung, stomach, colon, kidney, bone, prostate, renal, 
pancreatic, thyroid, and breast cancers. APN is involved in angiogenesis; the inhibition of new 
blood vessel formation which is an effective means of limiting both the size and metastasis of 
solid tumors. The expression of APN is higher in a variety of metastatic cancers than in normal 
tissues. 
The enzyme Aminopeptidase N (APN) is located on the gene ANPEP with its cytogenetic 
location of 15q26.1. Aminopeptidase N is a type II metalloprotease that belongs to the M 1 
family of the Ma clan. Ma clan consists of 967 amino acids with a short N-temlinal cytoplasmic 
domain, a single transmembrane palt, and a large cellular ectodomain containing the active site. 
APN has a molecular weight of 110,000 kDa. APN exists as membrane aminopeptidase N and 
soluble aminopeptidase N. It also can act as a receptor for human coronavirus [80]. APN is 
involved in several key functions such as the final digestion of peptides generated from 
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hydrolysis of proteins by gastric and pancreatic proteases which help to digest different kinds 
of proteins. APN plays a role in the processing of a variety of peptides. APN is involved in the 
cleavage of peptides bound to a major histocompatibility complex, angiogenesis, and promotes 
cholesterol crystallization. APN has catalytic activity on N-terminal amino acid, amide, or aiyl 
amide. It is seen in the epithelial cells of the kidney, small intestine and respirato1y tract as well 
as other plasma membranes. APN is found in the vasculature of tissues that undergo 
angiogenesis, in malignant gliomas, and lymph node metastases from multiple tumor types but 
not in blood vessels of nonnal tissues. A soluble fonn has been found in plasma and has been 
found to be elevated in plasma and effusions of cancer patients [8 1]. APN is a potent angiogenic 
regulator. It regulates angiogenesis. Accordingly, it is a potential target in cancer 
chemotherapy. Angiogenesis is the blood vessel formation from pre-existing vessels. Tumor 
angiogenesis described as the growth of new blood vessels that tumors need to grow. The 
ultimate purpose of angiogenesis is to supply nutrients and oxygen to the cells to proliferate 
uncontrollably. It is also imponant for the removal of waste products. Cancer cells can also 
spread to other pan s of the body through the blood and lymph systems. Tumor growth and 
metastasis are triggered by chemical signals from tumor cells in a phase of rapid growth and 
depend on angiogenesis and lymphangiogenesis, which means many tumor types first 
metastasize via lymphatic vessels to their regional lymph nodes [82, 83]. Cancer metastasis is 
an important batTier to cancer treatment and the cause of patient death. It is considered as a 
major cause of operation failure, postoperative relapse, and ultimately death. As stated earlier, 
metastasis is a complex, multistep process, where cancer cells spread from primary sites to new 
places. APN is being pursued by many as an important target against cancer metastasis and 
angiogenesis which suggests that synthetic APN inhibitors have the potential to overcome 
cancer metastasis and angiogenesis [84]. 
7.1. APN Expression in Normal Tissues and Malignant Neoplasms 
Arninopeptidase N can he expressed in hoth cancer cel ls and nonmalignant cells but it is 
still unclear where and how APN acts to regulate tumor angiogenesis. Reduction in 
angiogenesis more than likely accounts for the tumor growth defect that results from enzyme 
inactivation. APN is expressed not only by endothelial cells, but also by pericytes, myeloid, 
and mesenchymal stromal cells. These are central components of the environment that is 
needed for tumor to grow. Vascular endothelial growth factor (VEGF), an angiogenesis 
regulator, reduces the expression of APN at an early stage of tumor growth [85]. 
APN is also expressed in many tissues but especially on the membrane of the small 
intestine where it has an important role in peptide digestion. It can also be found in proximal 
tubules, on synaptic membranes of the central nervous system, on the surface of granulocytes 
and microphages. Positive APN expression has been found in non-haematopoietic cells such as 
fibroblasts, osteoclasts, and the epithelium that line the renal proximal tubules, intestine and in 
the bile duct canaliculi. In addition, other positive APN expression has been detected in 
hepatocellular, gall bladder, and renal carcinoma cell line. This wide distribution of APN 
proposes that it might be site dependent [86]. Aminopeptidase N has been linked specifically 
to cancer, because it has been identified as a cell-surface marker for malignant myeloid cells. 
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It has reached high levels of expression in association with the progression of tumors such as, 
breast, ovarian, and prostate cancer. APN expression was also detected in the n01mal colonic 
epithelium and in 30% of colonic carcinomas, acute myeloblastic leukaemia (AML) and some 
cases of acute lymphoblastic leukaemia (ALL) as well. H igh levels of APN expression in 
these two types of neoplasm has been related to the reduced success rate in reducing remission 
and shortened survival time especially in patients with ALL. After all the collaborative work 
conducted, APN is now considered as a potential marker for drug resistance [86] . 
It has been shown (in vivo) that inhibition of APN expression reduces prima1y tumor 
growth. They had tumor growth in WT-mice (positive APN) and APN-null mice. Control-
shRNA and APN-shRNA were delivered into the mice through short hairpin RNA (shRNA) 
which is primarily utilized during transient in vitro studies. Then B 16F 10 cells expressing 
control-shRNA and APN-shRNA were introduced subcutaneously into APN-mice and 
APN-null mice. After 11 days, the control-shRNA tumors showed a marked growth in WT 
mice. 
As supposed, these tumors showed reduced tumor volume and weight in the APN-null 
mice. To evaluate whether decreased vascularization resulting from APN deficiency accounted 
for the observed inhibition of tumor growth the tumor vasculature was subsequently analyzed 
by using antibodies against the endothelial marker, "CD3 1." This would provide insight if 
inhibition of tumor angiogenesis was associated with the loss of APN enzymatic activity. The 
results showed that large blood vessels were at first numerous when both malignant and host 
cells expressed APN in the LLC model. The results showed that APN clearly reduced blood 
vessel size and blood vessel density. Anti-APN inununofluorescence was also reduced tumors 
when the APN gene was deleted or knocked down in malignant cells. Finally, APN detection 
was located in tumor cells and was associated almost only with CD3 l-positive endotl1elial cells 
in control-shRNA tumors [85]. 
7.2. Targeted Drug Therapy 
Targeted cancer therapies are sometimes called "molecularly targeted dmgs/precision 
medicines" according to ilie National Cancer Institute (NCI). Targeted cancer tl1erapies use 
prodrugs that are widely used in the targeted delivery of cytotoxic compounds to cancer cells 
that block the growth and spread of cancer by interfering with specific molecular targets that 
are involved in the growth and spread cancer. The development of targeted therapies requires 
the identification of good targets that play a key role in cancer cell growth and survival such as 
APN. Metalloproteases such as APN, that are present in cancer cells but not nonnal cells that 
are more abundant in cancer cells would be potential targets. This is especially impo1tant if 
they are known to be involved in cell growth or survival. Targeted therapies do have some 
limitations. One is that cancer cells can become resistant to them over time by developing 
resistance. Resistance can occur in two ways: the target itself changes through mutations that 
are adapted since they increases the survival of the cancer and so the targeted therapy no longer 
interacts well with it or the tumor finds a new pathway to achieve tumor growth that does not 
depend on the target being treated [87]. 
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7.3. The Use of APN as a Target for Cancer Therapy 
APN is a ubiquitous enzyme that proliferates in a variety of tissues, muscles, and organs. 
It is described but not limited to as a multifunctional protein with enzymatic functions. Its other 
functions include operating as an antigen presentation and a receptor for some human viruses. 
Aminopeptidase N (APN) has two functions unrelated to its enzymatic activity. These include 
mediating tumor cell motility and serving as a receptor for tumor horning peptides (peptides 
that bring anti-cancer drugs to tumor cells). APN has recently emerged as one of the most 
promising approaches for cancer treatment. By being discovered as a receptor for a tumor-
horning peptide motif, NGR (Asp-Gly-Arg), which is capable of horning selectively to the 
tumor vasculature [88]. 
The tumor homing therapy (also known as targeted drug therapy) is the concept which is 
linked to anti-tumor drugs to a tumor-homing peptide. It specifically recognizes a receptor that 
is uniquely or overly expressed on tumor cell surfaces and actively guides the drugs to the 
tumor cell surfaces. APN and integrins are two of the most promising tumor-homing receptors. 
APN and integrin based tumor horning therapies are the only ones that are currently in clinical 
trials [89]. 
Curcumin, a gold-colored spice commonly used in the Indian subcontinent for its variety 
of uses such health care, belongs to the class "curcuminoids" (Figure 8), has been shown to 
exhibit antioxidant, anti-inflammatory, antiviral, antibacterial, antifungal, and anticancer 
activities. Therefore, it has the potential to fight against various malignant diseases, diabetes, 
allergies, arthritis, Alzheimer's disease, and other chronic illnesses. Curcumin exhibits 
activities like recently discovered tumor necrosis factor blockers [90]. Once curcumin is paired 
with APN, it binds to APN and irreversibly inhibits its activity. The direct interaction between 
curcumin with APN was confirmed both in vitro and in vivo studies. The screening of APN 
inhibitors was carried out using 3000 compounds from natural and chemical products. During 
the screening, curcurnin was quickly identified as a potent inhibitor of APN. Curcumin and its 
derivatives like demethoxycurcumin, bis-demethoxycurcumin, hydrazinocurcumin, and 
hestatin were testeci for their ability to block APN in vivo stuciies [88) 
In vivo enzyme assays that were carried out by monitoring the enzymatic degradation of a 
fluorescent substrate using cultured cells as a source of enzyme showed curcumin inhibited the 
enzymatic activity of APN. The APN activity of drug-untreated control was then normalized 
to 100% of the enzyme activity. The data suggest that the inhibition of APN by curcumin is 
irreversible and that the mode of inhibition of APN by curcumin is different from that of 
bestatin, which is a reversible and competitive inhibitor. Curcumin and other known APN 
inhibitors strongly inhibit APN-positive tumor cell invasion and basic fibroblast growth factor-
induced angiogenesis and when taken together results in the novel feature of exhibiting its 
irreversible inhibitor propenies that can be beneficial in the goal of inhibiting angiogenesis 
[88]. 
Bestatin (also known as Ubenimex), derived from Streptomyces olivoreticuli (Figure 9) 
inhibits a known 12 kinds of APN's. The fi.mction ofbestatin is to inhibit tumor cell invasion, 
and aminopeptidase activities of human metastatic tumor cells. This is an effect attributed to 
the inhibition of APN. A proximate study revealed that APN is the principal receptor for the 
NGR peptide motif and it was illustrated that this receptor is expressed only on the endothelial 
cells of angiogenic vasculature but not normal vasculature. Further studies have established 
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Figure 9. Some significant inhibitors of APN. 
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Aminopeptidase N is dysregulated in human malignancy which contributes to the 
neoplastic properties which interferes APN expression. Also, including the function or 
signaling that may lead to the development of novel anticancer drugs. This approach has been 
evaluated for some time and several investigational new drugs are cuITently under clinical 
investigation. The target may be used in several ways to employ anti-tumoral effects even if 
the targets are principally different. APN inhibition is being explored as a target for cancer 
therapy by exploring APN inhibitors that stop proliferative effects. They generally have broad 
and overlapping substrate specificity and inhibitors that are not expected to be specific. Some 
of these APN inhibitors with APN-inhibiting properties have entered early clinical trials. Such 
as, CHR-2797 (Tosedostat, Figure 9) which is a novel metalloenzyme inhibitor that is 
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converted into a pharmacologically active acid product (CHR-79888) inside cells. CHR-79888 
is a potent inhibitor of several intracellular aminopeptidases which exerts anti-proliferative 
effects against a variety of tumor cell lines in studies. APN is among other several compounds 
that are under preclinical development. These include novel synthetic compounds or structure 
analogs such as bestatin, dimethylaminoethyl ester (L YP). There are other more surprising 
compounds such as curcumin, a phenolic natural product, it has been noted an ineversible 
inhibitor of APN among its other many functions. Silencing APN showed evidence that it 
reduces the potency to metastasize. This new idea created of the use of differential enzyme 
expression as a basis for cancer therapy shows promise. However, the prodrng concept has also 
been thoroughly investigated but so far the results are mainly restricted to preclinical studies. 
Only with time will this area be developed further [91]. 
The battle to find better treatments to end the high failure rates in patients with advanced 
metastatic cancers continues. Targeting matrix metalloproteinases (MMPs) when treating 
cancer metastasis has large unsatisfactory results which leads to APN resulting as one of the 
most studied cancer therapeutic targets against cancer metastasis and angiogenesis. The 
extracellular mau·ix (ECM) is the principal banier of malignant cell dissemination. The ECM 
is a substrate of APN and matrix metalloproteinases MMPs. The way this multistep process 
occurs as APN degrades ECM to promote malignant cell invasion into the bloodstream. In the 
angiogenesis process, neo-endothelial cells invading through the ECM also need APN. 
Therefore, APN would be a key target to inhibit cancer metastasis and angiogenesis. 
Dysregulated expression and high-level exopeptidase activity of APN are found in various 
mammalian cancer cell lines in addition to neo-endothelial cells. This cancer cell lines include 
melanoma, prostate, ovarian, colon, renal and pancreas carcinomas. These could potentially 
benefit from treatment if breakthrough in evaluating APN and cell proliferation inhibition could 
be determined and carried through more in populations [84]. 
7.4. Expression of APN in Human Pancreatic Carcinoma 
The significance of Aminopeptidase N is expansive as it is involved in a variety of cancers 
and it is not limited to only one kind. This can be useful as new techniques and treatments 
become available they can be applied and administered on a broad variety of cancers. Pancreatic 
carcinoma is one of the dreadful cancers where APN plays a significant role in. Through studies 
using monoclonal antibody (MH8-11) that recognized APN inhibited human umbilical vein 
endothelial cells migration and capillary like fo1mation in the umbilical vein endothelial cells. 
It was investigated the expression of APN and the intratumor microvessel density in patients 
with pancreatic carcinoma. APN gene expression was detected by reverse transcriptase-PCR 
that was positive in 50% of the tumors and the APN protein was positive and detected by 
immunohistochemistry in 48% of tumors investigated in the 50 patients with pancreatic 
carcinoma. The median survival for patients with APN expression was significantly shorter 
than those without this expression. This concludes that APN can be used a new possible marker 
for these types of patients with pancreatic carcinoma. APN is positively correlated with 
angiogenesis for this cancer [92]. 
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7.5. Expression of APN in Human Colorectal Cancer 
In recent studies in colorectal cancer the significance of APN expression is being 
discovered. Study showed the activity of APN in tissue and plasma of colorectal cancer patients 
was higher it decreased overall survival of the patient. It was reported that mRNA levels of 
APN were lower in colorectal adenomas and adenocarcinomas than in the surrounding mucosa 
that was not involved. Higher plasmatic AON activity was therefore negatively correlated as 
previously mentioned. The detenninations of APN activity levels can be used as a possible 
marker that is inexpensive, minimally invasive way ro define the aggressiveness of colorectal 
cancer. This makes APN a good candidate to be a target molecule. Hopefully, this will initiate 
more research into better ways handle the diagnosing and treatment of colorectal cancer [93]. 
7.6. Aminopeptidase Nin Human Cervical Cancer 
Cervical cancer sta1ts in the cells lining the cervix. It is one of the most aggressive types 
of cancers. Cell surface APN/CD 13 activity in HeLa cells was used in the experiment and was 
discovered that the suppression of APN/CD 13 using bes ta tin, an inhibitor of APN/CD 13 
activity, could affect tumor radio-sensitivity in cervical cancer cells both in vitro and in vivo 
studies. Bestatin enhanced the effectiveness of radiotherapy and apoptosis by acting as a 
radiosensitizer both in vitro and in vivo studies. In colony fonnation assays, a significant decline 
in clonogenic survival was observed in bestatin treated cells. A combination of radiation and 
bestatin showed a significant prolongation of the tumor-doubling time compared with the 
control or radiation-alone groups. As radiation increased, APN/CD 13 activity the potential of 
bestatin to act as a radiosensitizer increased. The survival curves obtained for radiation alone 
and bestatin treated cells in combination with irradiation. A significant decline in clonogenic 
survival was observed in bestatin treated cells in combination with radiation. Funher studies 
are needed but there is a positive outlook in the possible use of bes ta tin to act as a radiosensitizer 
in ce1v ical cancer treatment. The inhibition of APN/CD13 activity may represent a new 
approach for improving the therapeutic efficiency of radiotherapy for uterine cervical cancer 
[94]. 
The expansive role of cancer research is breaching new frontiers to a problem in stagnancy. 
Finding new and innovative ways to approach such a malicious disease such as cancer is crucial 
for the overall well-being of the populous. With its unique propenies of being a zinc-dependent 
metalloproteinase readily involved with angiogenesis the life-line for tumor generation. New 
approaches exploring the role of APN such as being used as a cancer stem cell markers and 
becoming a leader in the development of anti-cancer and anti-inflammatory drugs and can serve 
as a target for delivering drugs into tumors and inhibiting angiogenesis. APN can even be 
involved in unonhodox approaches such as using pairing it curcumin to achieve irreversible 
effects on angiogenesis. Natural and synthetic inhibitors of APN activity have been 
characterized to inhibit angiogenesis. These inhibitors have revealed that APN can modulate 
bioactive peptide responses (pain management, vasopressin release) and to influence in1I11une 
functions and major biological events (cell proliferation, secretion, invasion, angiogenesis). 
Thus, APN inhibition may lead to the development of anti-cancer drugs primarily inhibiting 
. . 
ang1ogenes1s. 
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CONCLUSION 
Till date more than 73 proteins have been identified that play various roles in human 
cancers and the research is still under progress. Only a few key proteins have been discussed in 
this chapter along with their notable inhibitors. More research is necessary to identify different 
mechanism of actions of cancers as well as to develop more potent drugs with better potency 
(toxicity) towards cancer cells and less toxicity (side effects) towards normal cells. Research 
programs should be cooperated with awareness programs to fight against cancer worldwide in 
a meaningful manner. 
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